menu
    • menu
    [{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Arbormentis","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Arbormentis","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Arbormentis"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDAR channel","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Esmethadone Hydrochloride

    Menu

    Esmethadone Hydrochloride

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Relmada Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed

    Relmada Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Relmada to Discontinue Reliance II and Relight Phase 3 Studies of REL-1017

    Details : REL-1017 (esmethadone) NMDA receptor inhibitor, small molecule drug candidate, which is being evaluated as an adjunct treatment for the treatment of major depressive disorder.

    Product Name : REL-1017

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    December 09, 2024

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Relmada Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed

    Relmada Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Relmada Finds Phase 3 Reliance II Trial Futile At Interim Analysis

    Details : REL-1017 is a NCE and novel NMDAR channel blocker that targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, in major depressive disorder patients.

    Product Name : REL-1017

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    December 04, 2024

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Relmada Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed

    Relmada Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy ...

    Details : In the study, the REL-1017 treatment arm showed a MADRS reduction of 14.8 points at Day 28 versus 13.9 points for the placebo arm, a higher than expected placebo response.

    Product Name : REL-1017

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    October 13, 2022

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Relmada Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed

    Relmada Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Tr...

    Details : REL-1017, a new chemical entity and novel NMDA receptor channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatment of major de...

    Product Name : REL-1017

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    July 12, 2022

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Relmada Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed

    Relmada Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2022 Annual Meetin...

    Details : REL-1017 (esmethadone), new chemical entity and novel NMDA receptor channel blocker preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, in late-stage development for treatment of major depressive d...

    Product Name : REL-1017

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    May 25, 2022

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Relmada Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed

    Relmada Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology

    Details : REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatme...

    Product Name : REL-1017

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    April 29, 2022

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Relmada Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed

    Relmada Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Relmada Therapeutics to Present Data at the Ketamine & Related Compounds International Hybrid Conference 2022

    Details : REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatme...

    Product Name : REL-1017

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    April 04, 2022

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Relmada Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed

    Relmada Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Relmada Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential

    Details : Top-line results showed that all three doses of REL-1017 (25 mg, 75 mg and 150 mg) tested in recreational opioid users, demonstrated a highly statistically significant difference vs. the active control drug, oxycodone 40 mg.

    Product Name : REL-1017

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    July 27, 2021

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    Relmada Therapeutics

    U.S.A arrow
    Plastics Recycling EU
    Not Confirmed

    Relmada Therapeutics

    U.S.A arrow
    Plastics Recycling EU
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Undisclosed

    Sponsor : Arbormentis

    Deal Size : $165.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Relmada Therapeutics Announces the Acquisition of Novel Psilocybin and Derivates

    Details : Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.

    Product Name : REL-1017

    Product Type : Other Small Molecule

    Upfront Cash : $15.0 million

    July 20, 2021

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Undisclosed

    Sponsor : Arbormentis

    Deal Size : $165.0 million

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    10

    Relmada Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed

    Relmada Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Relmada Therapeutics to Present Data at the College on Problems of Drug Dependence 83rd Annual Scientific Meet...

    Details : REL-1017, a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development as an adjunctive treatment for MDD in adults.

    Product Name : REL-1017

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    June 15, 2021

    Lead Product(s) : Esmethadone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth